Trials / Not Yet Recruiting
Not Yet RecruitingNCT07282548
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
A Prospective Real-World Study Evaluating Objective Response Rate and Duration of Response of Tazemetostat Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Following at Least Two Prior Lines of Treatment
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 63 (estimated)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called lymphocytes. All participants will receive Tazemetostat as prescribed by their doctor in the routine clinical practice. The study will observe how participants respond to the treatment, how long the response lasts, and monitor safety, side effects and how well participants tolerate the treatment.
Detailed description
The results will be analyzed based on whether or not participants have a mutation in the Enhancer of zeste homolog 2 (EZH2) gene (known as EZH2 wild-type).
Conditions
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2031-06-30
- Completion
- 2031-06-30
- First posted
- 2025-12-15
- Last updated
- 2026-03-02
Source: ClinicalTrials.gov record NCT07282548. Inclusion in this directory is not an endorsement.